(Q34677912)

6 October 2017

An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care (English)

1 reference

prostate cancer screening

6 October 2017

1 reference

3

Alan W Partin

1 reference

6 October 2017

13

Peter Pinto

1 reference

6 October 2017

E David Crawford

1

1 reference

6 October 2017

Matt T Rosenberg

2

1 reference

6 October 2017

Matthew R Cooperberg

4

1 reference

6 October 2017

Michael Maccini

5

1 reference

6 October 2017

Stacy Loeb

6

1 reference

6 October 2017

Curtis A Pettaway

7

1 reference

6 October 2017

Neal D Shore

8

1 reference

6 October 2017

Paul Arangua

9

1 reference

6 October 2017

John Hoenemeyer

10

1 reference

6 October 2017

Mike Leveridge

11

1 reference

6 October 2017

Michael Leapman

12

1 reference

6 October 2017

Ian M Thompson

14

1 reference

6 October 2017

Peter Carroll

15

1 reference

6 October 2017

James Eastham

16

1 reference

6 October 2017

Leonard Gomella

17

1 reference

6 October 2017

Eric A Klein

18

1 reference

6 October 2017

language of work or name

English

0 references

publication date

19 July 2016

1 reference

6 October 2017

1 reference

6 October 2017

96

1 reference

6 October 2017

116-120

1 reference

Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

7 July 2018

Cancer statistics, 2015

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

A simple schema for informed decision making about prostate cancer screening

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

Expected population impacts of discontinued prostate-specific antigen screening

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

Overdiagnosis and overtreatment of prostate cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

The impact of recent screening recommendations on prostate cancer screening in a large health care system

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

The impact of PLCO control arm contamination on perceived PSA screening efficacy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

Baseline prostate-specific antigen testing at a young age.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

Mortality results from a randomized prostate-cancer screening trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

Prostate Cancer Screening.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

Trends in Management for Patients With Localized Prostate Cancer, 1990-2013.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen Screening.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

PSA screening: determinants of primary-care physician practice patterns

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

Balancing the harms and benefits of early detection of prostate cancer.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5568096

Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA)

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27450937

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.UROLOGY.2016.07.001

1 reference

release_jbtd4bqweffebplb6dgqfqfmy4

6 October 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jbtd4bqweffebplb6dgqfqfmy4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

6 October 2017

PubMed publication ID

27450937

1 reference